Limits...
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Li J, Saif MW - Biologics (2009)

Bottom Line: Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis.In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis.We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

View Article: PubMed Central - PubMed

Affiliation: Yale Cancer Center, Yale School of Medicine, New Haven CT, USA.

ABSTRACT
Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

No MeSH data available.


Related in: MedlinePlus

Schema of NSABP C-08 trial.46,47
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747341&req=5

f1-btt-3-429: Schema of NSABP C-08 trial.46,47

Mentions: Should we extrapolate the promising data of bevacizumab in advanced CRC into adjuvant setting? The answer to this question is no for now. Clearly current data from the National Surgical Adjuvant Breast and Bowel Project C-08 trial (NSABP C-08) did not support the use of bevacizumab in the adjuvant setting given lack of survival benefit. Allegra and colleagues published the safety data.46 This randomized phase III trial was designed to compare modified FOLFOX-6 (every 2 weeks for 12 cycles) with bevacizumab vs without bevacizumab. For the nonbevacizumab arm, patients received standard mFOLFOX-6 for a total of 12 cycles, while patients in the bevacizumab arm were offered bevacizumab maintenance after completion of 12 cycles of mFOLFOX-6 plus bevacizumab (Figure 1).


Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.

Li J, Saif MW - Biologics (2009)

Schema of NSABP C-08 trial.46,47
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747341&req=5

f1-btt-3-429: Schema of NSABP C-08 trial.46,47
Mentions: Should we extrapolate the promising data of bevacizumab in advanced CRC into adjuvant setting? The answer to this question is no for now. Clearly current data from the National Surgical Adjuvant Breast and Bowel Project C-08 trial (NSABP C-08) did not support the use of bevacizumab in the adjuvant setting given lack of survival benefit. Allegra and colleagues published the safety data.46 This randomized phase III trial was designed to compare modified FOLFOX-6 (every 2 weeks for 12 cycles) with bevacizumab vs without bevacizumab. For the nonbevacizumab arm, patients received standard mFOLFOX-6 for a total of 12 cycles, while patients in the bevacizumab arm were offered bevacizumab maintenance after completion of 12 cycles of mFOLFOX-6 plus bevacizumab (Figure 1).

Bottom Line: Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis.In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis.We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

View Article: PubMed Central - PubMed

Affiliation: Yale Cancer Center, Yale School of Medicine, New Haven CT, USA.

ABSTRACT
Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

No MeSH data available.


Related in: MedlinePlus